Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
23andMe Holding Co.

23andMe Holding Co. (ME) Stock Overview

Explore 23andMe Holding Co.’s financial performance, market position, analyst ratings, and future outlook.

ME●NASDAQ
HealthcareMedical - Diagnostics & Research
$0.61
$0.00(0.00%)
U.S. Market opens in 11h 44m

23andMe Holding Co. (ME)

Meyka AI Score

Z

Key Financials

Market Cap15.3M
P/E Ratio-0.13
EPS (TTM)$-17.39
ROE-42.03%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

ME Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of 23andMe Holding Co. (NASDAQ: ME) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, 23andMe Holding Co.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ME on the NASDAQ shows an RSI of 0.00, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.

Key metrics behind 23andMe Holding Co.'s NASDAQ-traded stock include a P/E ratio of -0.13 and a market capitalization of 15.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ME on the NASDAQ.

Price Performance (NASDAQ: ME)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
N/A
6-Month Change
N/A
Year-to-Date (YTD) Change
N/A
1-Year Change
-50.30%
3-Year Change
-98.65%
5-Year Change
-99.70%
All-Time (Max) Change
-99.69%

Contact Information

https://www.23andme.org
650 938 6300
349 Oyster Point Boulevard, South San Francisco, CA, 94080

Company Facts

5,600 Employees
IPO DateNov 23, 2020
CountryUS

Frequently Asked Questions